Navigation Links
New test for breast cancer will help guide treatment choices
Date:2/9/2009

SALT LAKE CITY One in eight women in the United States will receive a diagnosis of breast cancer in their lifetime, and it is the second leading cause of cancer-related death in women. Now a new test will help physicians determine the best possible treatment for each patient.

"Our research shows that there is a subset of women who can be cured without getting any treatment at all, other than a lumpectomy," explains Philip Bernard, M.D., an investigator at the University of Utah's Huntsman Cancer Institute and one of the senior authors on a multicenter study published in the Feb. 9 issue of the Journal of Clinical Oncology. "In women whose tumors have spread, we can predict with very high accuracy which women are going to respond to chemotherapy and which type of chemotherapy will work."

Only recently have scientists known that there are different breast cancer subtypes that lead to differences in outcome. The group narrowed down 50 genes that play an important role in identifying subtypes of breast cancer. By measuring the expression level of these genes in the tumors, they could determine how each individual will respond to standard therapies.

"This will give women peace of mind knowing that we're diagnosing cancer more accurately than ever before. We can tell them if they are likely to benefit from chemotherapy. If chemo isn't going to be beneficial, we shouldn't be giving it," Bernard says.

The research translates into a simple test that will be available nationwide this summer. The test has been validated on thousands of women with breast cancer and has shown to be useful in many different clinical situations.

Based on the type of tumor, doctors now will be able to prescribe only the treatment that will be most beneficial. For some patients that could mean no chemotherapy at all. For others it will mean targeted treatments that work best for that patient, and they will no longer have to endure needless chemotherapy.

Women whose tumors indicate a resistance to current treatments will be referred to clinical trials of investigational drugs and treatments, opening the door to more effective medications in the future.

The group is currently designing prospective clinical trials using the test, which they refer to as the Breast Bioclassifier. Bernard plans to run these trials at Huntsman Cancer Institute and collaborating institutions.

The research took 10 years to complete and involved cooperation among several research institutions. The multicenter study was led by researchers at the University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (Philip Bernard, M.D., assistant professor of pathology and medical director of molecular pathology at ARUP Laboratories); the University of North Carolina's Lineberger Comprehensive Cancer Center at Chapel Hill, N.C. (Charles Perou, Ph.D., associate professor of genetics and pathology); the University of British Columbia, Vancouver (Torsten Nielsen, M.D., Ph.D., associate professor of pathology); and Washington University Siteman Cancer Center, St. Louis, Mo. (Matthew Ellis, M.D., professor of medicine).

Bernard is one of the inventors of the test and has patents pending for the technology described in this news release. Additionally, he is a partner in the company University Genomics, along with colleagues at the Lineberger Comprehensive Cancer Center and Siteman Cancer Center. The company is working to commercialize the test.


'/>"/>

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences
Source:Eurekalert

Related biology news :

1. Statin therapy ineffective in breast cancer prevention
2. Hispanic women and breast cancer: An understudied group
3. Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
4. New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome
5. Fast-food diet cancels out benefits of breastfeeding in preventing asthma
6. Facebook flack regarding breastfeeding mothers
7. HWI scientist first in world to unravel structure of key breast cancer target enzyme
8. Team finds breast cancer gene linked to disease spread
9. Benefits of breastfeeding outweigh risk of infant exposure to environmental chemicals in breastmilk
10. Breast cancer genome shows evolution, instability of cancer
11. Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms of ... 2016 to 2021. The market is estimated to be USD 442.7 ... 2021. The growth of the biometric vehicle access system market is ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... ... January 20, 2017 , ... SpineFrontier, ... next evolution in spinal fusion, the MISquito Percutaneous Pedicle Screw System (part ... SpineFrontier is focused on technique driven product solutions that provide maximum efficiency ...
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... solutions for pharmaceutical research and development (R&D), today announced the launch of ... analysis and interpretation for the rapidly evolving field of precision medicine. ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
Breaking Biology Technology: